GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Trump Says Anthropic No Longer Seen as National Security Threat 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
WuXi AppTec (SS:603259), a leading Chinese pharmaceutical services company, announced plans to raise HK$7.70 billion (US$981 million) through a Hong Kong share placement to accelerate its global expansion and boost production capacity.
The company will issue 73.8 million new H-shares priced at HK$104.27 each, representing a 6.9% discount to its July 30 closing price. The placement accounts for approximately 2.51% of WuXi AppTec’s enlarged share capital and will be allocated to at least six institutional investors, according to the company’s statement.
WuXi AppTec stated that net proceeds of around HK$7.65 billion will be used mainly to fund overseas growth, with 90% earmarked for international expansion and capacity building projects. The remaining funds will be allocated for general corporate purposes.
This capital raising comes as WuXi AppTec continues to strengthen its global footprint in contract research, development, and manufacturing services amid rising demand for pharmaceutical outsourcing. The move aligns with the company’s strategy to enhance international operations and meet growing customer needs in key markets such as the United States and Europe.
The placement underscores investor confidence in WuXi AppTec’s growth prospects despite broader market volatility. By securing substantial funding, the company is positioned to expand its global infrastructure and maintain its competitive edge in the fast-evolving life sciences sector.
